Docoh
Loading...

MSON Misonix

Misonix, Inc. is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company's history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients.

Company profile

Ticker
MSON
Exchange
Website
CEO
Stavros G. Vizirgianakis
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
112148932

MSON stock data

(
)

Calendar

6 May 21
31 Jul 21
30 Jul 22
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jun 20 Jun 19 Jun 18 Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Misonix earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 30.91M 30.91M 30.91M 30.91M 30.91M 30.91M
Cash burn (monthly) 640.05K 734.31K 1.25M 1.54M 554.78K 1.02M
Cash used (since last report) 2.57M 2.95M 5.02M 6.18M 2.23M 4.09M
Cash remaining 28.35M 27.97M 25.89M 24.73M 28.69M 26.82M
Runway (months of cash) 44.3 38.1 20.7 16.0 51.7 26.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Jun 21 Patton Thomas M Stock Option Common Stock Grant Aquire A No No 22.18 15,000 332.7K 15,000
30 Jun 21 Vizirgianakis Stavros G. Stock Option Common Stock Grant Aquire A No No 22.18 150,000 3.33M 150,000
30 Jun 21 Klugewicz Sharon W Stock Option Common Stock Grant Aquire A No No 22.18 15,000 332.7K 15,000
30 Jun 21 Laviolette Paul A Stock Option Common Stock Grant Aquire A Yes No 22.18 15,000 332.7K 15,000
30 Jun 21 Jonathan Jay Waggoner Stock Option Common Stock Grant Aquire A No No 22.18 15,000 332.7K 15,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

60.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 55 59 -6.8%
Opened positions 7 6 +16.7%
Closed positions 11 5 +120.0%
Increased positions 15 20 -25.0%
Reduced positions 18 18
13F shares
Current Prev Q Change
Total value 260.83M 474.65M -45.0%
Total shares 10.57M 10.36M +2.0%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
SV Health Investors 1.69M $33.19M 0.0%
1315 Capital 1.69M $21.18M 0.0%
SVLSF Vi 1.69M $21.18M 0.0%
BLK Blackrock 866.88K $16.98M +2.6%
Vanguard 694.37K $13.6M +4.7%
Royce & Associates 655.2K $12.84M +180.8%
Pura Vida Investments 504.76K $9.89M +2.9%
Juniper Investment 465.92K $9.13M 0.0%
Tamarack Advisers 350K $6.86M +16.7%
Soleus Capital Management 301.33K $5.9M 0.0%
Largest transactions
Shares Bought/sold Change
Royce & Associates 655.2K +421.9K +180.8%
Roubaix Capital 0 -127.12K EXIT
Dimensional Fund Advisors 47.86K -77.57K -61.8%
Essex Investment Management 0 -59.58K EXIT
Tamarack Advisers 350K +50K +16.7%
Integral Health Asset Management 45K +45K NEW
Harbert Fund Advisors 41.5K +41.5K NEW
Vanguard 694.37K +31.19K +4.7%
Squarepoint Ops 0 -29.08K EXIT
NTRS Northern Trust 145K -28.16K -16.3%

Financial report summary

?
Competition
MedtronicStrykerMimedxMedtronic
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: begun, detail, efficacy, exercise, explicit, gradual, gradually, lesser, mentioned, professional, qualified, vaccine, VAT, worsen
Removed: American, College, divert, diverting, evaluating, presence, recommended, strength, surgeon, usage